Plain language summary of the CARTITUDE-4 study on ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma
This Plain Language Summary of publication article (PLSP) from Future Oncology covers the phase 3 CARTITUDE-4 clinical trial, which compared ciltacabtagene autoleucel (cilta-cel) with standard treatments for multiple myeloma. Participants, who had not responded to 1 to 3 prior treatments, including lenalidomide, were studied to assess the effectiveness of cilta-cel in improving their condition.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma’ and was published in The New England Journal of Medicine.
Visit The New England Journal of Medicine using the link to read the original article.